Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

170 Stories from Volunteers, Donors & Supporters

12

Donor

Rating: 5

A non- profit pharmaceutical company? That sounds like the best way to see the future. And medicinal research that could be of not only of assistance but provide full recovery with little to no side effects. This organization wants to change the world in leaps and bounds. PTSD is a serious disorder that effects countless veterans, victims of assault & violence, or becoming traumatized by other varieties of harm. Their studies have proven safety and efficiency for a medication that other companies ignored because it would not be of profit (patent expiration). Healing for the sake of helping, not greed, is the path I hope the world is now on.

Review from Guidestar

11

Donor

Rating: 5

MAPS has helped to educate me regarding the potential medical use of psychedelic compounds. Because these substances are anathema in the society at large, MAPS has been terrific in funding education and research.

Review from Guidestar

8

Donor

Rating: 5

For many of us, one of the most profound experiences in our lives is connected to psychedelics. After a comet like explosion in the 60's, this misunderstood tool became like the kid in class who misbehaves and is sent to the back corner of the room. MAPS, like a wise teacher, coaxed that kid back to the center of the room, to its proper place. Thank god for MAPS!

Review from Guidestar

9

Donor

Rating: 5

I am a 64 yr old, middle class non-drug using female. All of my experimentation was when I was young. But I've never forgotten the experiences. There is a place for hallucinogenic drugs in mankind's future. Moderation (and thoughtfulness and reasonableness) are all reasons that I support MAPS. Their place in our future must be supported.

Review from Guidestar

8

Donor

Rating: 5

I'm a member of MAPS since two years ago. Though I'm french, I support this organization because it's simply the most efficient and professional in this field. They are focused in science and medical research, do an impressive job to make that happens and it's actually happening thanks to them. They get government approval, they gather all the best specialists in psychedelic research worldwide.

Review from Guidestar

8

Donor

Rating: 5

I have been a member of MAPS for three years now. I am constantly impressed by their level of professionalism and dedication in this field. It is wonderful to see well balanced research taking place with an aim to mainstreaming psychedelic medicines for the benefit of all.

Review from Guidestar

9

Donor

Rating: 5

MAPS may be one of the most important medical nonprofit organizations in existence. It is dedicated to pushing science and medicine to new heights and challenges society to think a little more outside the box.

Review from Guidestar

9

Donor

Rating: 5

MAPS is leading the way into the future of psycho-medical treatments with relevant and coherent psychedelic research that can be scientifically proven and empirically validated. Funded as a non-profit organisation and backed by a highly qualified and dedicated team of fellow human beings - all of whom are compassionate and understanding towards people undergoing P.T.S., psychological distress from terminal illnesses, migraines, and other debilitating ailments - they do their utmost to ensure that anyone undergoing a psychological affliction is given every chance to re-intergrate back into a healthy and vibrant mode of living without being crippled or impaired by unnecessary and prolonged medical treatments. Without this essential work into the psychological benefits of psychedelics, modern medicine may well linger far too long in a false Cartesian dualistic understanding of mind and body: one that sees these two essences of a human being as discreetly separate from one another, to be treated independently of each other... Rather than seeing a more accurate representation of the mind and body as monism than heals itself interdependently. This is probably the most important medical research being conducted in our time. MAPS needs you... And, believe it or not, you need MAPS! So donate today and support the future of this sustainable and highly effective medical treatment... Wake up and see it all for what it really is... The key to our well Being!

Review from Guidestar

12

Donor

Rating: 5

Thus far I have only been able to help MAPS monetarily, but the information that they have provided me with has been invaluable. I am a professional in the medical field, and I, like many of my colleagues, believe whole heartedly in the potential of psychedelic science to cure disease and enrich lives. MAPS is a well run, forward thinking organization that deserves whole-hearted support.

Review from Guidestar

7

Donor

Rating: 5

MAPS has consistently achieved progression in utilising the natural capacity of the mind to enhancing its potential that was previously thought improbable, all through proven scientific endeavour. It is leading the way in research clarifying therapeutic substances and techniques that will ultimately be of great use for helping return people to a healthy state.

Review from Guidestar